On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.
Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania
Episode Topics1:48 What’s the difference between the FDA and Centers for Medicare and Medicaid Services?
3:58 What is the purpose of sharing a proposal and allowing public comment after? Is it possible the proposal could change?
9:09 What are your key takeaways from the CMS proposal?
11:58 Who’s being charged the cost of the treatment if it is part of a clinical trial?
18:33 What does this decision, with its focus on research often occurring in major urban medical centers, mean for equity and access?
26:27 What is the future of Alzheimer’s disease research after the CMS decision?
Show NotesRead the Center for Medicare and Medicaid Services’s press release about the proposed coverage policy, view submitted public comments about the decision, and submit your own comment.
Learn more about Dr. Jason Karlawish’s work and writing at his website.
Listen to our four-part episode series with Dr. Jason Karlawish about his book, The Problem of Alzheimer’s, on our website (episode 1, episode 2, episode 3, episode 4).
Mixed Dementia, Explained
The Case for Disclosing Biomarker Results to Alzheimer’s Research Participants
Promoting Open Science and Community Engagement with the National Institute on Aging
Moving into the Digital Era of Alzheimer’s Disease Research
National Efforts to Standardize Brain Scan Data for More Accurate Alzheimer’s Risk Predictions
Protecting Participant Privacy and Making Predictions Using Alzheimer’s Data
The Future of Sharing and Accessing Alzheimer’s Disease Data
Introducing the National Alzheimer’s Coordinating Center
Study Shows APOE e4 Not Associated with Alzheimer’s Disease in American Indian Populations
Improving Registries and Representation in Alzheimer’s Disease Research
Highlights from the 2022 Alzheimer’s Association International Conference
COVID-19 and Its Effects on the Brain
Apathy and Alzheimer’s Disease: Plenary Preview with Dr. Krista Lanctôt
Scientific Importance of Diversity in Alzheimer’s Disease Research
Delirium and Dementia: Plenary Preview with Dr. Sharon Inouye
Non-Pharmacological Care for People with MCI and Dementia: Plenary Preview with Dr. Linda Lam
Opening Doors to Research Participants: Making Scientific Conferences Accessible to the Public
The World’s Largest Forum for Alzheimer’s Research: Introducing the AAIC 2022 Special Series
Study Shows Do-Not-Resuscitate Orders Can Lead to Worse Care, Increase Death Rates
‘Finding the Right Words’: Author Interview with Cindy Weinstein and Bruce Miller
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks